As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...

Taking a page from Eli Lilly and their LillyDirect online pharmacy ... Lilly’s Next-Generation Triple Agonist GLP-1 Drug Looks Very Promising Lilly has also been working on their next-generation ...

Feb 20 - Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its February monthly meeting, Chief Scientific Officer Dan ...

Lilly figures it won't have to be conservative with launch supplies of orforglipron, unlike the situation with Mounjaro and Zebpound. For its injectable GLP-1s, which were met with immense ...

Teladoc Health has partnered with Eli Lilly's LillyDirect and pharmacy provider GiftHealth to expand access to Zepbound, a GLP-1 drug prescribed for weight loss. The partnership allows Teladoc ...

Lilly’s chances of leading the GLP-1 race long-term are higher, but investors should brace for volatility if competition intensifies or regulators crack down on pricing. The edge Eli Lilly has ...

"Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company best known for developing and selling GLP-1 medications for diabetes and obesity. Shares detracted from performance as recent GLP-1 ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...